Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 1
---
2025 and December 31, 2024, respectively; liquidation preference of $8,750 at September 30, 2025 
     2,292  
     1,249,999 
  
    Series D convertible preferred stock, $0.0001 par value; 12,500 shares authorized; 9,800 and 0 issued and outstanding at September 30, 2025 and December 31, 2024, respectively; liquidation preference of $12,250,000 at September 30, 2025 
     7,408,866  
     - 
  
    Series A convertible preferred stock, $0.0001 par value; 12,580 shares authorized; 1,429 and 1,894 issued and outstanding at September 30, 2025 and December 31, 2024, respectively; liquidation preference of $1,786,250 at September 30, 2025 
     1,287,315  
     1,708,396 
  
    Series B convertible preferred stock, $0.0001 par value; 626 shares authorized; 0 and 273 issued and outstanding at September 30, 2025 and December 31, 2024, respectively; No liquidation preference at September 30, 2025 
     -  
     218,051 
  
    Class A common stock; $0.0001 par value; 1,000,000,000 shares authorized; 1,496,398 and 120,794 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 
     150  
     12 
  
    Additional paid-in capital 
     73,055,709  
     67,142,276 
  
    Stock subscription receivable 
     -  
     (1,295,444)
  
    Accumulated deficit 
     (86,297,494) 
     (70,917,853)
  
    Total stockholders’ deficit 
     (4,543,162) 
     (1,894,563)
  
    Total liabilities and stockholders’ deficit 
    $3,911,394  
    $6,206,929 

See accompanying notes to the condensed consolidated
financial statements

Reflects a 1-for